Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04NRB
|
|||
| Former ID |
DCL000294
|
|||
| Drug Name |
Cetilistat
|
|||
| Synonyms |
Cametor; Cetilistat [INN]; ATL 962; ATL962; ATL-962; Cetilistat (JAN/USAN/INN); 2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y] | Phase 3 | [1], [2] | |
| Obesity [ICD-11: 5B81; ICD-10: E66] | Phase 3 | [1], [2] | ||
| Company |
Alizyme; Takeda; Norgine B.V.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H39NO3
|
|||
| Canonical SMILES |
CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C=C2)C)C(=O)O1
|
|||
| InChI |
1S/C25H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-28-25-26-23-18-17-21(2)20-22(23)24(27)29-25/h17-18,20H,3-16,19H2,1-2H3
|
|||
| InChIKey |
MVCQKIKWYUURMU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 282526-98-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14928313, 24222842, 46049526, 79998193, 81044360, 92252048, 92719489, 93310783, 96025888, 121147451, 125346920, 126620765, 126651071, 126671085, 128652237, 131308796, 134338950, 135252832, 135313712, 137001360, 140274838, 152054794, 160676376, 162188868, 162258147, 164830800, 165235292, 174528660, 187072381, 196106282, 198943777, 223384844, 223666797, 223796471, 226699838, 249721013, 251893243, 251962974, 252448580, 252450870
|
|||
| ChEBI ID |
CHEBI:134721
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gastric triacylglycerol lipase (LIPF) | Target Info | Modulator | [1] |
| BioCyc | Triacylglycerol degradation | |||
| KEGG Pathway | Glycerolipid metabolism | |||
| Metabolic pathways | ||||
| Fat digestion and absorption | ||||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| WikiPathways | Triacylglyceride Synthesis | |||
| Fatty Acid Beta Oxidation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007 Mar;31(3):494-9. | |||
| REF 2 | Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.